MAR 25, 2019 10:59 AM PDT

Discovery of Biomarker Target for Melanoma

WRITTEN BY: Nouran Amin

According to a study published in the journal Cancer Research, researchers have discovered a biomarker that could serve as a possible therapeutic target for melanoma. The marker is microphthalmia-associated transcription factor (MITF)—which is is a protein that plays a crictcal role in the maintenance of the melanocyte lineage (cells that make melanin), as well as the differentiation of normal and malignant melanocytes and melanoma cell survival.

Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

"We have now detected the first useful chemical inhibitor of MITF," said corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine.

Over the past decade genetic mutations in human melanomas have been extensively examined—regardless, the role of epigenetic alterations in the development and progression of melanomas is still not well understood.

Specifically, scientists discovered that the inhibition of the epigenetic p300 Histone Acetyltransferase (HAT) enzyme stops the growth of human melanoma cells and cells that express the MITF protein are sensitive to this inhibition. The inhibition can hold many broad implications for the treatment of pigmented lesions in the skin which could potentially be used for the topical treatment of hyperpigmentation.

The study opens the doors to the endless pursuit for additional epigenetic approaches to cancers.

"When human melanoma cell lines were evaluated for growth effects using the chemical inhibitor of p300 HAT, the cell lines that were most sensitive to drug treatment were those that expressed high levels of MITF suggesting that MITF expression levels can predict melanoma sensitivity to such therapies," explained Alani, who also is chief of dermatology at Boston Medical Center.

Source: EurekAlert

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
OCT 16, 2020
Drug Discovery & Development
FDA Warns Against NSAIDs After Week 20 of Pregnancy
OCT 16, 2020
FDA Warns Against NSAIDs After Week 20 of Pregnancy
The US Food and Drug Administration (FDA) has warned against using nonsteroidal anti-inflammatory drugs (NSAIDs) from 20 ...
OCT 03, 2020
Drug Discovery & Development
Treating Gut-Leakiness
OCT 03, 2020
Treating Gut-Leakiness
A drug called tofacitinib, also called Xeljanz , was found to treat permeability defects in the intestines. Tofacitinib ...
NOV 06, 2020
Drug Discovery & Development
New Vaccine Shows Promise for Herpes
NOV 06, 2020
New Vaccine Shows Promise for Herpes
The World Health Organization estimates that over 500 million people have Herpes Simplex Virus Type 2 (HSV-2), a sexuall ...
NOV 09, 2020
Drug Discovery & Development
New Immunotherapy Shows Promise for MS
NOV 09, 2020
New Immunotherapy Shows Promise for MS
Researchers from Thomas Jefferson University in Philadelphia are studying an immunotherapy that has shown early pro ...
NOV 02, 2020
Drug Discovery & Development
Type 2 Diabetic Drug Combo Proves Effective
NOV 02, 2020
Type 2 Diabetic Drug Combo Proves Effective
A common first-line therapeutic for type 2 diabetes is the metformin drug used to stabilize blood glucose levels. Althou ...
Loading Comments...